FogPharma vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
FogPharma develops cell-penetrating mini-proteins (CPMPs) to target intracellular cancer drivers like beta-catenin and FOXM1 that are undruggable by antibodies; raised $174M including a $100M Series C in 2023;
About
FogPharma is a clinical-stage biopharmaceutical company founded in 2015 by Gregory Verdine and headquartered in Cambridge, Massachusetts, developing a novel class of cancer therapeutics based on cell-penetrating mini-proteins (CPMPs). Traditional cancer drugs fall into two broad categories: small molecules that can penetrate cells but struggle to bind complex protein surfaces, and antibodies that bind complex surfaces with high specificity but cannot enter cells. FogPharma's CPMPs are designed to do both — penetrate cell membranes and engage large, complex intracellular protein targets that cause cancer but have historically been considered undruggable.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.